UC, UC Health to launch Phase 3 clinical trial for COVID-19 vaccine
Vaccine uses a genetic code to produce proteins that may generate protective antibodies
Researchers at the University of Cincinnati and UC Health will host a Phase 3 clinical trial to evaluate the effectiveness of a vaccine for COVID-19, the respiratory illness caused by the novel coronavirus SARS-CoV-2.
UC is one of approximately 90 sites across the United States selected for the study, which will administer the vaccine candidate mRNA-1273 to volunteer participants and monitor its efficacy in eliciting an immune response that provides protection from COVID-19. The National Institute of Allergy and Infectious Diseases, (NIAID), part of the National Institutes of Health, is funding the study.
Carl Fichtenbaum, MD, of the UC College of Medicine Division of Infectious Diseases, medical director of the COVID-19 vaccine trial. Photo/Colleen Kelley/UC Creative + Brand
“UC was chosen because we have a proven track record of high-quality research and are the number one site in the NIAID-funded, AIDS Clinical Trials Group in the U.S. We are proud to bring leading-edge research to Cincinnati so that we can help our community battle the COVID-19 pandemic and be part of the solution,” said Carl Fichtenbaum, MD, professor in the Division of Infectious Diseases at the UC College of Medicine and a UC Health physician.
Fichtenbaum is co-investigator of the study and will serve as medical director.
Read the full story here.
Featured photo of COVID-19 vials by Colleen Kelley/UC Creative + Brand
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Stay up on all UC's COVID-19 stories, read more #UCtheGood content, or take a UC virtual visit and begin picturing yourself at an institution that inspires incredible stories.
Related Stories
Hoxworth Blood Center teams up with Cyclones in February for biggest blood drive event of year
January 30, 2026
Hoxworth Blood Center, University of Cincinnati, is teaming up with the Cyclones and other local businesses to host its annual Queen City Blood Drive on Feb. 9-11 at Heritage Bank Center. If you can’t attend this event, Hoxworth encourages you to still make donating a #HoxworthHabit and give blood this February.
Research findings may lead to new test for endometriosis
January 30, 2026
Endometriosis affects one in 10 women worldwide, and many go years before diagnosis. Symptoms include chronic pelvic pain, heavy bleeding during menstruation and/or sexual intercourse, bloating and fatigue. Katie Burns’ research at the University of Cincinnati is focused on creating a new, non-invasive test for endometriosis, using white blood cells as biomarkers. Burns, PhD, is an associate professor in the Department of Environmental and Public Health Sciences in the College of Medicine.
Trials find electromagnetic pulses aid stroke recovery
January 30, 2026
The University of Cincinnati's Joseph Broderick, MD, was featured in a U.S. News & World Report article commenting on new research being presented at the International Stroke Conference that found stroke survivors might benefit from electromagnetic pulses that stimulate their brains and spur on their recovery.